Search
London Healthcare Week: Manchester, UK based F2G, which booked a $100M financing in September, is focused on developing therapies for fungal infections
CEO Francesco Maria Lavino describes the unmet need in this area and the science behind how F2G combats it. Plus, learnings from an FDA...
Nov 22, 2024
Seoul based ABL Bio is emerging as a leader in bi-specific antibodies - with programs in CNS, oncology, and a unique approach to making ADCs bi-specific as well
Founder & CEO Sang Hoon Lee describes the science that sets ABL apart and where he sees Korea biotech headed.
Nov 22, 2024
Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea
He explains the power of protein degradation, and the upside to Orum's targeted delivery approach. Plus, selling an asset to Bristol...
Nov 22, 2024
London Healthcare Week: A discussion on treating neurodegenerative diseases with the CEO of AC Immune
Andrea Pfeifer describes the rationale for treating neurodegenerative disease with immunotherapies, and the importance of treating people...
Nov 22, 2024
London Healthcare Week: As the company gears up for its first phase 3 trials, MindMed's CEO says he sees a tailwind of regulatory support for the psychedelics space
Robert Barrow discusses MindMed's LSD based program that is going into phase 3 studies for generalized anxiety disorder and major...
Nov 21, 2024
The Liver Meeting: Vir Biotechnology presented data from programs for chronic hepatitis B and chronic hepatitis delta
Vir Chief Medical Officer Mark Eisner discusses the MARCH Phase 2 study results for hepaitis B, and Hôpital Beaujon Professor of...
Nov 21, 2024
From Seoul: AIGEN Sciences is using generative AI for drug discovery and development - in addition to already having 16 programs, the company earlier this year struck an ADC deal with Hanmi
CEO Jaewoo Kang, a computer scientist, describes AIGEN's computational heavy platform. Plus, he discusses three of the most advanced...
Nov 21, 2024
Visiting the largest cell therapy company in Korea, GC Cell, and learning about its approved immunotherapy for hepatocellular carcinoma, its CAR-NK programs in development, and more
CEO James Park describes GC Cell's history, its approved cell therapy that has been on the market in Korea since 2007, and its programs...
Nov 21, 2024
London Healthcare Week: After announcing FIH data from its oral GLP in obesity in September, Terns is also getting ready to release initial data in December for its allosteric BCR ABL cancer program
CEO Amy Burroughs walks us through what the company saw in the obesity program, and previews what to expect from initial cohorts in CML...
Nov 21, 2024
The Liver Meeting: Rectify Pharma presented preclinical data supporting its hypothesis of improving the function of dysfunctional membrane proteins: ABCB4 and BSEP
CEO Rajesh Devraj describes the company's focus on membrane protein function and normalizing it with small molecules, in this case for...
Nov 20, 2024
From Seoul: AimedBio is leveraging patient data and its expertise in antibody discovery and design to develop first-in-class antibody-drug conjugates with unique targets - the first program is FGFR3
CEO Nam-Gu Her describes the factors that make AimedBio unique in how it designs ADCs, and discusses how it landed on FGFR3 as its first...
Nov 20, 2024
London Healthcare Week: Pharvaris is developing an oral bradykinin B2-receptor antagonist for HAE - both in the acute and prophylaxis settings
CEO Berndt Modig describes the science behind creating both immediate release capsuls and extended release tablets. Successfully...
Nov 20, 2024
London Healthcare Week: Rinri Therapeutics is working on a hearing loss solution that uses stems cells that are turned into the precursors of auditory neurons, cells that cannot naturally regenerate
CEO Simon Chandler describes why the company is focusing on auditory neurons and the process that Rinri uses to create them. Plus, plans...
Nov 20, 2024
London Healthcare Week: Oculis is aiming to redefine ophthalmology through methods like an eye drop technology that can reach the back of the eye and precision medicine like patient selection
CEO Riad Sherif introduces us to the company's programs in areas such a diabetic macular edema and dry eye. A phase 2 study in acute...
Nov 19, 2024
London Healthcare Week: VectorY Therapeutics is delivering antibodies to the CNS using an AAV vector - the first program for ALS is scheduled to go into the clinic next year
CEO Sander van Deventer describes the science behind delivering antibodies this way, and learnings he has taken away from the gene...
Nov 19, 2024
From Japan, Takeda's CEO Christophe Weber talks about the company's Japanese roots, but global transformation - plus, five key pipeline assets
He describes Takeda's HQ and R&D facilities in Japan, but also how global markets have grown to dominate the company's business since he...
Nov 18, 2024
Mursla Bio presented data at The Liver Meeting suggesting that its EvoLiver diagnostic test can spot liver cancer among cirrhotic patients with 86% early-stage sensitivity and 88% specificity
CEO Pierre Arsѐne describes how the test analyses hepatocyte extracellular vesicles, and how he believes this result surpasses the...
Nov 18, 2024
London Healthcare Week: The CEO of MoonLake Immunotherapeutics gives an overview of the company's Nanobody platform, including the lead program that targets IL-17A and IL-17F
Jorge Santos da Silva explains the properties that he believes give Nanobodies versatility and an edge over traditional antibodies, and...
Nov 18, 2024
Sagimet Biosciences presented a subset analysis of the FASCINATE-2 P2 trial of denifanstat in MASH patients at The Liver Meeting showing improved fibrosis based on an AI pathology analysis method
CEO David Happel describes how this fatty acid synthase (FASN) inhibitor works, and the AI method suggesting the therapy is having an...
Nov 18, 2024
With programs using both somatic cells and iPSCs, and an NK platform for oncology in the works, Japan's Healios aims to be a leader in regenerative medicine
CEO Hardy Kagimoto describes the company's programs, including how Multistem could soon be conditionally approved in Japan and is...
Nov 17, 2024
.png){kind=logo}
